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and treated group using a metabolic disease cohort in 
which candidate subjects have participated. For classify-
ing into three groups, we primarily relied on the records 
of physicians’ comments, prescriptions, treatment history, 
lipid profiles and test results from medical equipment 
aimed at the diagnosis for atherosclerosis or cardiovascu-
lar disease. After collecting the final 54 plasma samples, 
we analyzed and compared the expression levels of miR-
33a and ABCA1 at the plasma levels. In the comparison 
of plasma levels of the three groups, the miR-33a expres-
sion level of athero-risk group was 5.01-fold higher than 
that of normal group. Meanwhile, in the culture of foam 
cells transfected with anti-miR-33a oligonucleotides, the 
miR-33a level significantly decreased, while ABCA1 level 
significantly increased. The results suggest that enhanced 
expression of miR-33a might induce cholesterol accu-
mulation and aggravate inflammation in vessel walls by 
suppressing the expression of ABCA1 in macrophages. 
Thus, plasma miR-33a can be considered as a candidate 
biomarker of atherosclerosis.
Keywords Plasma biomarker · MiRNA-33a · ABCA1 · 
MicroRNA oligonucleotides · Atherosclerosis · 
Foam cells
Introduction
In the development of atherosclerotic lesions, macrophages 
accumulate in the intima of the artery. Early lesions are 
rarely detected in atherosclerosis as the apoptotic cells are 
cleared by efferocytosis. When macrophages participate in 
the formation of atherosclerotic plaques, they appear to have 
a decreased capacity to migrate, which contributes to fail-
ure to resolve inflammation and makes smooth muscle cells 
Abstract In order to investigate whether plasma 
microRNA-33a (miR-33a) can be a biomarker for the early 
detection of atherosclerosis and to reexamine the assump-
tion that miR-33a represses the expression of ABCA1, we 
compared the expression levels of miR-33a and ATP-bind-
ing cassette A1 (ABCA1) using human plasma and super-
natants of macrophage cultured media. We first separated 
ample number of plasma samples from left-over whole 
blood samples based on the criteria for normal or dys-
lipidemia, and stored them at −20 °C until use. Then we 
selected 18 plasma samples for each normal, athero-risk 
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freeze–thawing cycles. Moreover, they are stable even in 
RNase-rich plasma, probably because they are sequestered 
within exosomes, microvesicles, or associated with either 
Ago2 or HDL [19–21]. Compared to large molecular weight 
plasma RNA, the exosomal miRNAs and plasma miRNAs 
were stable under different storage conditions and there 
were no significant influences on plasma miRNAs [22]. 
Serum miRNAs were also resistant to repeated freeze–thaw 
cycles. When serum was treated for 3 h in low (pH = 1) or 
high (pH = 13) pH solutions, miRNAs remained stable [23, 
24]. Therefore, plasma, like serum, is an excellent source of 
miRNAs for research on hyperlipidemia and coronary artery 
disease [25]. Accordingly, this study investigated whether 
plasma miR-33a can be used as a diagnostic marker for the 
early detection of atherosclerosis.
Materials and methods
Sample selection criteria and classification of groups
Among the individuals who visited a laboratory center for 
medical checkups between February 21 and March 31, 
2013, we carefully selected final 54 subjects who were 
participating in a metabolic disease cohort and had signed 
informed consent to allow us to use their left-over blood 
specimens. We obtained informed consent from medical 
check-up examinees at the beginning of their participation 
in the metabolic disease cohort and we have complied with 
the ethical principles outlined in the Declaration of Helsinki.
participate in the inflammatory process. In these advanced 
plaques, macrophages secrete inflammatory cytokines and 
bring about necrosis and apoptosis [1, 2], and the fibrous 
cap becomes thinner and prone to rupture, thereby causing 
thrombosis [3].
During reverse cholesterol transport (RCT), ATP-binding 
cassette A1 (ABCA1) moves cholesterol and phospholipids 
from the inner to the outer leaflet of the membrane, from 
where apolipoprotein A-1 (ApoA-1) carries the lipid compo-
nents to nascent high-density lipoprotein (HDL) to generate 
larger HDL [4, 5]. In transgenic mice, the over-expression of 
human ABCA1 resulted in increased cholesterol efflux from 
macrophages. This implies that enhanced ABCA1 activity 
can protect against atherosclerosis in vivo [6].
If expression of microRNA-33a (miR-33a) is aberrantly 
increased in macrophages, ABCA1 expression would be 
downregulated and the RCT may not function properly. 
In hepatocytes and macrophages, ABCA1 is antithetically 
expressed to the expression of miR-33a (Fig. 1) [7, 9, 10, 
12, 17].
The over-expression of miR-33a/b reduces both fatty 
acid oxidation and insulin signaling in hepatic cell lines 
[7–10]. However, when an anti-miR-33a oligonucleotide 
was delivered into cells, the inhibitory effect of miR-33a on 
ABCA1 expression was alleviated [11, 12]. Thus, anti-miR-
33a oligonucleotides are being investigated as a therapeutic 
tool to enhance either ABCA1 or HDL expression [13–18].
miRNAs maintain their stability under harsh condi-
tions such as high temperature, extreme-pH values, stor-
age at room temperature for extended periods, and repeated 
Fig. 1 Elevated miR-33a 
represses the expression of 
ABCA1, leading to decreased 
HDL formation. Under normal 
circumstances, ABCA1 moves 
cholesterol and phospholipids 
from the inner to the outer 
leaflet of the macrophage 
membrane, thereby facilitating 
HDL formation. During the 
progression of atherosclerosis, 
aberrantly elevated miR-33a 
represses ABCA1 expression. 
Under conditions of decreased 
expression of ABCA1, the cho-
lesterol efflux cannot function 
properly, resulting in decreased 
HDL formation. miR-33a 
might be secreted into plasma 
or transported to the liver via 
microvesicles, Ago2 or HDL
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Final collection of 54 plasma samples
For the classification of the subjects into Normal, Treated 
and Atherosclerosis-risk (Athero-risk) groups, we primar-
ily focused on the records of physicians’ comments on the 
individual health status with respect to atherosclerosis, car-
diovascular disease, ischemic heart disease and myocardial 
infarction. For better selection and discrimination of the 
groups, we attentively reviewed individuals’ cohort records 
on treatment history, prescriptions, and various tests such 
as, thermal conductivity, carotid ultrasound, pulse wave 
velocity, abnormal Q-wave, high levels of LDL, TG, fast-
ing blood sugar (FBS), creatine kinase, and T-cholesterol/
HDL ratio in addition to the physicians’ opinion. For a study 
on miR-33a as a candidate biomarker of atherosclerosis, we 
finally collected 18 samples for each group. The collected 
plasma samples were kept at −20 °C until use (Fig. 2).
Isolation of miRNAs from plasma samples and culture 
media
miRNAs were isolated from human plasma samples or 
supernatant of foam cell culture. The frozen plasma and 
supernatants were thawed at 42 °C for 1 h. At the beginning 
of the study, the stabilities of miRNAs were verified using 
a batch of miRNAs such as miR-16, miR-33a, and miR-
33b under the above conditions. Then, 400 μL of plasma or 
supernatant was treated with 600 μL Isogen (NipponGene, 
Toyama, Japan) at room temperature for 5 min, followed by 
200 μL chloroform (Sigma–Aldrich, St Louis, MO, USA) 
and incubated for 10 min at room temperature. The sample 
was centrifuged at 15,000×g for 15 min, the upper aqueous 
phase was separated, and 500 μL isopropyl alcohol (Sigma–
Aldrich) was added before incubating at room temperature 
for 15 min. After incubation, the sample was centrifuged 
again to precipitate RNA. The pellet was dried completely 
and dissolved in diethylpyrocarbonate-treated water. RNA 
concentrations were measured using a NanoDrop (Thermo 
Fisher Scientific, San Jose, CA, USA) instrument.
Quantification of miR-33a levels in human plasma and 
supernatant of foam cell cultures
Total RNA from samples were reverse transcribed using 
Mir-X™ miRNA First-Strand Synthesis Kit (Clontech, 
Mountain View, CA, USA) and real-time PCR was per-
formed using SYBR® Advantage® qPCR Premix (Clon-
tech). PCR primers for miRNA-33a were prepared as 
follows: miRNA-33a forward, 5′-GTGCATTGTAGTTGC 
ATTGCA-3′ [11, 12, 15], while the 3′ primer was included 
in the kit as a reverse primer. PCR was performed using 
a Rotor-Gene 6000 (Corbett Life Science, Concorde, 
NSW, Australia). As an internal control, a known amount 
Primary sample selection and separation of plasma
samples
First, at chemistry section on-the-spot, the subjects were 
classified into two groups ‘Normal’ and ‘Hyperlipidemic’, 
based on the criteria of five lipid parameters such as, 
total-cholesterol (T-cholesterol), low-density lipoprotein 
(LDL), HDL, triglycerides (TG), and the T-cholesterol/
HDL ratio. If a sample subject met four of the five require-
ment criteria, then the subject was classified into ‘Normal’ 
group, and if met three of the hyperlipidemic criteria, then 
classified into ‘Hyperlipidemic’ groups (Table 1).
Following ‘on-the-spot’ dyslipidemia classification, two 
technologists at hematology section selected every left-over 
whole blood samples of the corresponding individual, and 
separated plasma fraction from the whole blood samples by 
centrifugation at 800×g for 20 min within 3 h after blood 
collection. Then, selected candidate plasma samples were 
stored at −20 °C one by one.
Table 1 Sampling criteria of normal, atherosclerosis-risk, and treated 
groups
Groups 1° selection 
criteria(based on on-
the-spot test results of 
5 lipid parameters)
2° selection criteria
(based on records of 
physician comments, test 
results and cohort data)
Normal T-Chol <200 mg/dL Normal group
No significant physi-
cians’ clinical opinions 
along with at least 
four of the five lipid 
items should be within 
reference ranges of the 
laboratory (left)
LDLc <130 mg/dL




Hyperlipidmic T-Chol ≥240 mg/dL Athero-risk group
Physicians’ temporary 
decisions on the 
cardiovascular status 
with respect to athero-
sclerosis (CVD, IHD, 
MI). Never treated or 
prescribed for the past 
five years on the above 
disease AND at least 
three of the five lipid 




Any treatment records 
and prescription his-
tory related with above 
diseases during for the 
past five years
LDLc ≥160 mg/dL




CVD cardiovascular disease, IHD ischemic heart disease, MI myo-
cardial infarction, T-chol t tal cholesterol, LDLc low-density lipo-
protein cholesterol, HDLc high-density lipoprotein cholesterol, TG 
triglycerides
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five times with wash buffer, 90 µL tetramethylbenzidine 
substrate was added, and the samples were incubated at 
37 °C for 20 min. After incubation, 50 μL stop solution 
was added immediately. ABCA1 concentrations were cal-
culated from the optical density value of the sample and a 
standard curve.
THP-1 cell culture, differentiation into macrophages, 
and preparation of ox-LDL
THP-1 cells were cultured in RPMI1640 medium (Hyclone, 
Logan, UT, USA) supplemented with 10 % (v/v) fetal calf 
serum (Gibco, Uxbridge, UK) at 37 °C in an atmosphere 
containing 5 % CO2. The THP-1 cells were induced to dif-
ferentiate into macrophages by the addition of 250 ng/mL 
phorbol 12-myristate 13-acetate (PMA, Sigma–Aldrich, St 
Louis, MO, USA) for 72 h. Human LDL (Sigma–Aldrich) 
was oxidized with 7.5 μmol/L CuSO4 (Sigma–Aldrich) at 
37 °C for 24 h. The oxidative reaction was stopped by the 
addition of 0.01 mmol/L EDTA. The lipoprotein concen-
tration in each sample was determined by a BCA protein 
assay kit (Thermo Fisher Scientific), and oxidized-LDL was 
stored at 4 °C before use.
Transfection with miRNAs and foam cell induction
To reexamine the assumption that miR-33a suppresses the 
expression of ABCA1 in macrophages, we first designed 
of synthetic U6 snRNA was added to each sample, which 
was evaluated using Clontech Mir-S miRNA First Strand 
Synthesis and a SYBR RT-PCR kit. We calculated the ∆Ct 
of miR-33a in each sample using the internal control, U6 
snRNA, by subtracting the Ct of U6 from the Ct of miR-
33a. Then, we calculated the respective ∆∆Ct in each sam-
ple by subtracting the mean ∆Ct of the normal group from 
the ∆Ct of each sample. We calculated the 2−∆∆Ct values for 
each sample and determined the mean value for each group. 
Finally, we compared the expression levels of miR-33a in 
plasma of three groups and in culture supernatant of five 
types of macrophages.
Quantification of ABCA1 levels in human plasma and 
supernatant of foam cell cultures
ABCA1 concentration was measured using an ABCA1 
ELISA kit (Cusabio, Wuhan, China) as per the manufac-
turer’s instructions. Briefly, human plasma samples were 
diluted with sample diluents (1:200) and 100 μL of each 
sample and the standard were added into the wells of a 
96-well plate. The plate was incubated at 37 °C for 2 h 
and 100 μL of biotin-antibody was added to each well. 
The plate was incubated at 37 °C for 1 h, and each well 
was washed with wash buffer. One hundred microliters of 
horseradish peroxidase-avidin was loaded to each well and 
incubated at 37 °C for 1 h. For supernatant of foam cell 
culture, each supernatant sample was aspirated and washed 
Fig. 2 Two-step selection processes for 54 samples. First, in order to 
sort out normal and hyperlipidemic samples, the dyslipidemic indi-
viduals were selected according to the criteria of serum lipid levels. 
The left-over whole blood samples of target individuals were carefully 
selected, and separated plasma samples were stored in a deep freezer 
until use. In the secondary selection, the hyperlipidemic samples were 
further classified into ‘treated’ or ‘non-treated athero-risk’ ones based 
on the records of physicians’ comments on the individual’s status with 
respect to atherosclerosis, cardiovascular disease, ischemic heart dis-
ease, and myocardial infarction
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(Fig. 3a–c). Their normalized values for miR-33a were 
1.0 ± 0.24, 5.01 ± 1.03, and 1.93 ± 0.74, respectively, show-
ing that plasma miR-33a levels in the athero-risk group 
were significantly higher than the normal group (p < 0.01), 
while there was no significant difference between normal 
and treated groups (Fig. 3d).
Plasma ABCA1 level of the treated group was lower 
than that of athero-risk group
Under the assumption that miR-33a suppresses the expres-
sion of ABCA1, we compared the plasma ABCA1 lev-
els of three groups through ELISA assay. The plasma 
ABCA1 concentrations were 14.1863 ± 1.2853 ng/mL, 
9.9295 ± 1.3694 ng/mL and 7.9358 ± 1.2952 ng/mL in nor-
mal, athero-risk and treated groups, respectively (Fig. 3e–g) 
showing the plasma concentrations of ABCA1 of athero-
risk (p < 0.05) and treated (p < 0.01) group were lower than 
that of athero-risk group (Fig. 3h). Through the Fig. 3a–c, 
e–g, we could notice easily the antithetical expression pat-
terns between miR-33a and ABCA1.
Plasma miR-33a levels showed strong correlations with 
lipid items such as LDL and total cholesterol
In age- and sex-adjusted correlation analysis, plasma miR-
33a has positive correlations with LDL and T-cholesterol 
(p < 0.01). As expected, T-cholesterol/HDL ratio has positive 
correlations with LDL, T-cholesterol, and TG (p < 0.001), 
but an inverse correlation with HDL (p < 0.001). Of note, 
FBS has a positive correlation with T-cholesterol (p < 0.05). 
However, we could not find an inverse correlation between 
the miR-33a and ABCA1 in the plasma expressions 
(Table 2).
miR-33a seems to inhibit the lipid efflux from cells by 
suppressing ABCA1 expression
Since we could not find direct causal-effects of miR-33a and 
ABCA1 at the human plasma level, we adopted an extrapo-
lation of foam cell (from THP1 cell) cultures. We measured 
the concentration of miR-33a in the supernatant and the 
level of lipid accumulation caused by suppressed ABCA1. 
To figure out the causal-effect of the miR-33a and ABCA1, 
we prepared four types of foam cells through transfections 
of different miRNA oligonucleotides.
In the comparison of lipid accumulations by oil red O 
staining among the four types of foam cells, the ox-LDL 
treated macrophages (control foam cells) showed low 
levels of lipid accumulation (Fig. 4a), while the non-ox-
LDL treated macrophages showed a near absence of lip-
ids (Fig. 4b). In contrast, foam cells transfected with the 
miR-33a-mimic showed increased staining intensity within 
five types of macrophages (untreated macrophages; con-
trol foam cells treated with ox-LDL but not-transfected; 
and three batches of foam cells transfected with differ-
ent miRNA oligonucleotides as follows: the first group of 
foam cells were transfected with 10 nM ‘miR-33a-mimic’ 
(5′-GTGCATTGTAGTTGCATTGCA-3′), the second group 
transfected with ‘anti-miR-33a’ (5′-TGCAATGCAACTAC 
AATGCAC-3′), and the third group transfected with 
‘miR-33a-mismatched’ (5′-TCCAATCCAACTTCAATCA 
TC-3′) (Bioneer, Daejeon, Korea). The miRNA transfections 
were carried out with Lipofectamine RNAiMAX reagent 
for 24 h (Invitrogen, Carlsbad, CA, USA) in OptiMEM 
medium (Invitrogen). Then, the foam cells were prepared 
by treating the macrophages with 50 μg/mL ox-LDL in 
RPMI1640 medium supplemented with 10 % (v/v) fetal calf 
serum. Foam cell induction was carried out for 72 h.
Oil red-O staining for compa ison of lipid accumu ation
Cultured cells were washed with phosphate-buffered saline 
and fixed with 10 % (v/v) formalin (Sigma–Aldrich) for 1 h 
at room temperature. The cells were treated with 60 % (v/v) 
isopropyl alcohol and incubated for 5 min at room tempera-
ture. Cells were dried and incubated with 0.21 % (w/v) oil 
red O staining solution (Sigma–Aldrich) for 10 min at room 
temperature. The cells were then washed and lipid accumu-
lation within the cells was examined using an optical micro-
scope (CKX-41, Olympus, Tokyo, Japan).
Statistical analysis
Using the IBM SPSS Statistics 21.0 (IBM Corporation, 
Armonk, New York, USA) software, we performed age- 
and sex-adjusted correlations, one-way ANCOVA, one-
way ANOVA and ROC analysis. In the ROC analysis, 
54 individuals were all plotted for non-lipid items such 
as miR-33a, FBS, diastolic blood pressure and ABCA1. 
As a default, the statistical software chooses the optimal 
cut-off point across a series of cut-off points. The opti-
mal cut-off point would be the shortest distance between 
the point of SN = 1 and SP = 1 and any points on the ROC 










The plasma levels of miR-33a were significantly 
increased in athero-risk group
The mean ± standard deviations of plasma levels of miR-
33a (2−∆∆Ct) in normal, athero-risk, and treated groups were 
3.15 ± 0.76, 15.77 ± 3.24, and 6.09 ± 2.34, respectively 
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level was 5.86-fold higher than that of control foam cells 
(p < 0.001). Meanwhile, foam cells transfected with anti-
miR-33a and miR-33a-mismatched showed 1.0- and 0.83-
fold expression, respectively (Table 3; Fig. 4f).
The ABCA1 levels in supernatant of cultured foam cells 
transfected with miR-33a-mimic decreased 0.46-fold as 
compared with the control foam cells (p < 0.001). Further, 
the cells indicating greater amounts of lipid accumulation 
within these cells (Fig. 4c). Meanwhile, in foam cells trans-
fected with anti-miR-33a or miR-33a-mismatched, the lipid 
accumulations return to the level similar to or even lower 
than (Fig. 4d–e) the control level (Fig. 4f–g).
Supernatant miR-33a levels were greatly increased in 
foam cells transfected with miR-33a-mimic. The miR-33a 
Fig. 3 Plasma expression levels of miRNA 33a and ABCA1 in nor-
mal, athero-risk, and treated groups. The plasma expression levels of 
miR-33a are shown in their 2−∆∆Ct values of the 18 subjects in normal, 
athero-risk and treated groups (a–c). The normalized plasma level of 
miR-33a of athero-risk group was 5.01-fold higher than that of normal 
group (p < 0.01) (d). Plasma levels of ABCA1 of 18 subjects of nor-
mal, athero-risk and treated groups are shown (e–g) along with their 
normalized ratios (h). Compared to the normal group, the expression 
levels of ABCA1 of athero-risk and treated groups decreased 0.7-fold 
(p < 0.05) and 0.55-fold (p < 0.01), respectively
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by suppressing ABCA1 expression. The oil-red O staining 
seems to support the assumption that miR-33a would inhibit 
the cellular expression of ABCA1 (Fig. 4c–e). It seems that 
miR-33a suppress the expression of ABCA1 at the cellular 
level.
ABCA1 levels in the supernatant of foam cells transfected 
with anti-miR-33a and miR-33a-mismatched were increased 
by 1.69- and 1.75-fold, respectively, compared to the con-
trol foam cells (p < 0.01) (Table 3). Taken together, miR-
33a might have inhibited the lipid efflux from macrophages 
Table 2 Age-adjusted partial correlations among lipid items, FBS, miR-33a, and ABCA1
HDL LDL T-Chol TG TC/HDL FBS miR33a ABCA1
HDL 1.000 −0.171 −0.080 −0.394** −0.624*** 0.037 0.056 0.214
LDL 1.000 0.954** 0.113 0.793*** 0.266 0.363** −0.076
T-Chol 1.000 0.340* 0.789*** 0.297* 0.422** −0.017
TG 1.000 0.514*** 0.115 0.206 0.038
TC/HDL 1.000 0.118 0.265 −0.042
FBS 1.000 0.038 −0.268
miR33a 1.000 −0.016
ABCA1 1.000





Fig. 4 Lipid accumulation in foam cells transfected with different 
miRNA oligonucleotides and their secreted levels of miR-33a and 
ABCA1 in foam cell culture media. The five types of cells differently 
treated or transfected with miRNA oligonucleotides and stained with 
oil red O afterwards showed different levels of lipid accumulations. 
Moderate staining intensity in Ox-LDL-treated control foam cells 
(a), very low staining intensity in non-LDL treated macrophages (b), 
strong staining intensity in foam cells transfected with miR-33a-mimic 
(c), moderate intensities in foam cells transfected with anti-miR-33a 
and miR-33a-mismatched, respectively(d–e). Supernatant miR-33a 
level of foam cells that are transfected with miR-33a-mimic was 5.7-
fold higher than that of control group (f). Supernatant ABCA1 level of 
cells transfected with miR-33a-mimic decreased 0.43-fold of that of 
control group, while those of cells transfected with anti-miR33a and 
miR-33a-mismatched were 1.69- and 1.75-fold higher than that in the 
control group, respectively (g)
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which can be carried from cells to plasma more easily via 
microvesicles or Ago2.
Nevertheless, the expression levels of miR-33a and 
ABCA1 showed antithetical expressions in the culture 
supernatants of macrophages that are transfected with 
miR-33a-mimic and anti-miR-33a respectively (Table 3). 
The lipid accumulations shown in the oil red-o staining 
(Fig. 4f–g) support the antithetical expressions (Fig. 4a–e) 
suggesting that ABCA1 expression might be suppressed by 
miR-33a, at the cellular level.
Hu et al. have reported that ABCA1 expression in foam 
cells was suppressed by other miRNAs than miR-33a such 
as miR-144-3p. They found that treatment with miR-144 
mimics resulted in a significant increase in lesion area of 
ROC curves showed good discriminating ability of 
miR-33a for a candidate biomarker of atherosclerosis
AUCs (Area under curves) and 95 % confidence intervals 
for miR-33a, FBS, Diastolic blood pressure and ABCA1 
were 0.82 (0.70–0.94), 0.79 (0.66–0.91), 0.67 (0.52–0.82) 
and 0.47 (0.30–0.63), respectively. Among the four non-
lipid items, the plasma miR-33a showed the best discrimi-
nating ability with an AUC of 82 % as a potential biomarker 
for athero-risk diagnosis. In the ROC analysis for miR-33a, 
sensitivity, specificity, positive predictive value, negative 
predictive value, and odds ratio to detect atherosclero-
sis were 66.7, 86.1, 70.6, 83.8, and 12.4 %, respectively 
(Fig. 5).
Discussion
In this study, we used a laboratory cohort data that has been 
developed by a diagnostic laboratory. However, the spe-
cially designed cohort could not provide us with complete 
information on the checkup individuals such as, type and 
dose of prescribed drugs and duration of treatments of the 
treated group.
miR-33a has been already known to suppress the cellular 
expression of ABCA1 in macrophages or hepatocytes [9, 
10, 12, 29]. To evaluate the applicability of plasma miR-33a 
as a biomarker for atherosclerosis, we compared the plasma 
miR-33a levels among the normal, athero-risk and treated 
groups. Contrary to our expectation, there was no inverse 
correlation between miR-33a and ABCA1 at plasma level 
(Table 2). Moreover, the expression level of plasma ABCA1 
in athero-risk group was lower than that of treated group 
(Fig. 3e–h). It seemed that plasma levels of ABCA1 cannot 
reflect the cellular expression levels of ABCA1 properly. 
We cast doubts on that the membrane protein ABCA1 can-
not be easily transported to the plasma as well as miR-33a, 
Fig. 5 ROC curve for miR-33a as a single biomarker for the early 
detection of atherosclerosis. Multiple ROC curves were derived for 
non-lipid items. Area under curves and 95 % CIs for miR-33a, FBS, 
Diastolic blood pressure and ABCA1 were 0.82 (0.70–0.94), 0.79 
(0.66–0.91), 0.67 (0.52–0.82) and 0.47 (0.30–0.63), respectively
 
Macrophages and foam cellsa Exp levels of miR-33ab ABCA1 Exp (ng/mL)
N Mean ± SD N Mean ± SD
Foam cell (control) 3 1.00 ± 0.28*** 4 4.854170 ± 0.81208**
Macrophages (non-Ox-LDL) 3 0.03 ± 0.01 4 4.010774 ± 0.81573
Foam cell with miR-33a-mimic 3 5.86 ± 0.59 4 2.117754 ± 0.41407
Foam cell with anti-miR-33a 3 1.02 ± 0.24 4 8.211216 ± 0.85186
Foam cell with 
miR-33a-mismatched
3 0.83 ± 0.08 4 8.504994 ± 0.98983
The expression levels were compared through one-way ANOVA
**p < 0.01
***p < 0.001
aFoam cells transfected with miR-33a oligonucleotides
bNormalized ratio
Table 3 Expression levels of 
miR-33a and ABCA1 in the 
supernatant of different macro-
phage cultures
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atheromatous plaque formation in apolipoprotein E−/− mice. 
Moreover, treatment with an miR-144 mimic had an effect 
on the secretion of the inflammatory cytokines such as TNF-
α, IL-1β and IL-6 [27]. Thus, we should investigate further 
how miRNAs regulates the expression of ABCA1.
In addition to miR-33a or miR-144, a few miRNAs such 
as miR-148a, miR-26 and miR-27a/b are known to regu-
late ABCA1 expression and HDL metabolism. Especially 
silencing miR-148a could increase the ABCA1 expression 
and HDL-cholesterol [28].
For quantification of miRNAs, the absolute quantifica-
tion method and the construction of a standard curve may be 
preferable to U6 snRNA as an internal control.
FBS levels were significantly higher in athero-risk and 
treated groups as compared with normal group (p < 0.001). 
It is well known that aberrant expression of miR-33b is 
involved in the metabolism of fatty acid oxidation and insu-
lin signaling because miR-33b targets genes such as CPT1A, 
CROT, NPC, AMPK, SIRT6, and IRS2 [9, 14].
In conclusion, plasma levels of miR-33a in athero-risk 
group were fivefold higher than normal group. miR-33a 
seems to play an important role in inhibiting cholesterol 
efflux in macrophages via suppression of ABCA1 expres-
sion. Accordingly, plasma miR-33a can be a candidate bio-
marker for the early detection of atherosclerosis.
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